These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39163262)

  • 1. An engineered NKp46 antibody for construction of multi-specific NK cell engagers.
    Lee RB; Maddineni S; Landry M; Diaz C; Tashfeen A; Yamada-Hunter SA; Mackall CL; Beinat C; Sunwoo JB; Cochran JR
    Protein Eng Des Sel; 2024 Jan; 37():. PubMed ID: 39163262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.
    Lipinski B; Arras P; Pekar L; Klewinghaus D; Boje AS; Krah S; Zimmermann J; Klausz K; Peipp M; Siegmund V; Evers A; Zielonka S
    Protein Sci; 2023 Mar; 32(3):e4593. PubMed ID: 36775946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
    Gauthier L; Morel A; Anceriz N; Rossi B; Blanchard-Alvarez A; Grondin G; Trichard S; Cesari C; Sapet M; Bosco F; Rispaud-Blanc H; Guillot F; Cornen S; Roussel A; Amigues B; Habif G; Caraguel F; Arrufat S; Remark R; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E
    Cell; 2019 Jun; 177(7):1701-1713.e16. PubMed ID: 31155232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies.
    Pfeifer Serrahima J; Schoenfeld K; Kühnel I; Harwardt J; Macarrón Palacios A; Prüfer M; Kolaric M; Oberoi P; Kolmar H; Wels WS
    Front Immunol; 2024; 15():1457887. PubMed ID: 39267747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
    Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
    MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
    Zhang M; Lam KP; Xu S
    Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes.
    Yossef R; Gur C; Shemesh A; Guttman O; Hadad U; Nedvetzki S; Miletić A; Nalbandyan K; Cerwenka A; Jonjic S; Mandelboim O; Porgador A
    PLoS One; 2015; 10(2):e0118936. PubMed ID: 25719382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1.
    Glasner A; Ghadially H; Gur C; Stanietsky N; Tsukerman P; Enk J; Mandelboim O
    J Immunol; 2012 Mar; 188(6):2509-15. PubMed ID: 22308311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1.
    Halfteck GG; Elboim M; Gur C; Achdout H; Ghadially H; Mandelboim O
    J Immunol; 2009 Feb; 182(4):2221-30. PubMed ID: 19201876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
    Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
    Front Immunol; 2021; 12():801368. PubMed ID: 35087526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression.
    Glasner A; Isaacson B; Viukov S; Neuman T; Friedman N; Mandelboim M; Sexl V; Hanna JH; Mandelboim O
    Sci Rep; 2017 Oct; 7(1):13090. PubMed ID: 29026144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium.
    Satoh-Takayama N; Dumoutier L; Lesjean-Pottier S; Ribeiro VS; Mandelboim O; Renauld JC; Vosshenrich CA; Di Santo JP
    J Immunol; 2009 Nov; 183(10):6579-87. PubMed ID: 19846871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses.
    Narni-Mancinelli E; Jaeger BN; Bernat C; Fenis A; Kung S; De Gassart A; Mahmood S; Gut M; Heath SC; Estellé J; Bertosio E; Vely F; Gastinel LN; Beutler B; Malissen B; Malissen M; Gut IG; Vivier E; Ugolini S
    Science; 2012 Jan; 335(6066):344-8. PubMed ID: 22267813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKp46 regulates allergic responses.
    Ghadially H; Horani A; Glasner A; Elboim M; Gazit R; Shoseyov D; Mandelboim O
    Eur J Immunol; 2013 Nov; 43(11):3006-16. PubMed ID: 23878025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.
    Bar-On Y; Charpak-Amikam Y; Glasner A; Isaacson B; Duev-Cohen A; Tsukerman P; Varvak A; Mandelboim M; Mandelboim O
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.